Is DYN or EVMN more profitable?

Evommune's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Evommune N/A N/A N/A

Does the media prefer DYN or EVMN?

In the previous week, Dyne Therapeutics had 4 more articles in the media than Evommune. MarketBeat recorded 15 mentions for Dyne Therapeutics and 11 mentions for Evommune. Dyne Therapeutics' average media sentiment score of 0.09 beat Evommune's score of -0.15 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IDYA or EVMN more profitable?

Evommune's return on equity of 0.00% beat IDEAYA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Evommune N/A N/A N/A

Does the media prefer IDYA or EVMN?

In the previous week, Evommune had 9 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 11 mentions for Evommune and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.63 beat Evommune's score of -0.15 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, EVMN or ALMS?

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 35.72 -$68.87M -$9.50 N/A Alumis $24.05M 140.48 -$243.32M -$1.98 N/A

Is EVMN or ALMS more profitable?

Evommune has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Evommune's return on equity of 0.00% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Alumis -2,825.70% -88.79% -70.72%

Does the media favor EVMN or ALMS?

In the previous week, Evommune had 8 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Evommune and 3 mentions for Alumis. Alumis' average media sentiment score of 0.63 beat Evommune's score of -0.15 indicating that Alumis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Alumis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ADPT or EVMN?

In the previous week, Evommune had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 11 mentions for Evommune and 8 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.60 beat Evommune's score of -0.15 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, EVMN or QURE?

Evommune has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evommune $13M 35.72 -$68.87M -$9.50 N/A uniQure $16.10M 163.79 -$198.97M -$3.48 N/A

Is EVMN or QURE more profitable?

Evommune has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Evommune's return on equity of 0.00% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A uniQure -1,154.42% -145.81% -27.15%

Does the media favor EVMN or QURE?

In the previous week, uniQure had 16 more articles in the media than Evommune. MarketBeat recorded 27 mentions for uniQure and 11 mentions for Evommune. uniQure's average media sentiment score of 0.73 beat Evommune's score of -0.15 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evommune (EVMN) Competitors

$12.89 +0.07 (+0.56%)

Closing price 03:59 PM Eastern

Extended Trading

$12.75 -0.14 (-1.09%)

As of 07:56 PM Eastern

Compare

EVMN vs. DYN, IDYA, ALMS, ADPT, and QURE

Should you buy Evommune stock or one of its competitors? MarketBeat compares Evommune with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evommune include Dyne Therapeutics (DYN), IDEAYA Biosciences (IDYA), Alumis (ALMS), Adaptive Biotechnologies (ADPT), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry.

How does Evommune compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Evommune (NYSE:EVMN) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Dyne Therapeutics had 4 more articles in the media than Evommune. MarketBeat recorded 15 mentions for Dyne Therapeutics and 11 mentions for Evommune. Dyne Therapeutics' average media sentiment score of 0.09 beat Evommune's score of -0.15 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

96.7% of Dyne Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Evommune's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Evommune	N/A	N/A	N/A

Evommune has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A

Dyne Therapeutics currently has a consensus price target of $34.17, suggesting a potential upside of 48.10%. Evommune has a consensus price target of $45.63, suggesting a potential upside of 253.90%. Given Evommune's higher probable upside, analysts clearly believe Evommune is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86

Summary

Evommune beats Dyne Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Evommune compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Evommune (NYSE:EVMN) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

98.3% of IDEAYA Biosciences shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Evommune had 9 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 11 mentions for Evommune and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.63 beat Evommune's score of -0.15 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences currently has a consensus target price of $50.69, suggesting a potential upside of 34.63%. Evommune has a consensus target price of $45.63, suggesting a potential upside of 253.90%. Given Evommune's stronger consensus rating and higher possible upside, analysts clearly believe Evommune is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86

Evommune's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Evommune	N/A	N/A	N/A

Evommune has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	15.12	-$113.70M	-$1.60	N/A
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A

Summary

Evommune beats IDEAYA Biosciences on 9 of the 15 factors compared between the two stocks.

How does Evommune compare to Alumis?

Evommune (NYSE:EVMN) and Alumis (NASDAQ:ALMS) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Evommune currently has a consensus target price of $45.63, indicating a potential upside of 253.90%. Alumis has a consensus target price of $40.30, indicating a potential upside of 52.08%. Given Evommune's stronger consensus rating and higher probable upside, research analysts clearly believe Evommune is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Evommune has higher earnings, but lower revenue than Alumis. Alumis is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A
Alumis	$24.05M	140.48	-$243.32M	-$1.98	N/A

In the previous week, Evommune had 8 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Evommune and 3 mentions for Alumis. Alumis' average media sentiment score of 0.63 beat Evommune's score of -0.15 indicating that Alumis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Evommune's return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Alumis	-2,825.70%	-88.79%	-70.72%

Summary

Evommune beats Alumis on 9 of the 14 factors compared between the two stocks.

How does Evommune compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Evommune (NYSE:EVMN) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Adaptive Biotechnologies has higher revenue and earnings than Evommune. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	12.24	-$59.50M	-$0.33	N/A
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A

Adaptive Biotechnologies currently has a consensus price target of $20.50, indicating a potential downside of 3.26%. Evommune has a consensus price target of $45.63, indicating a potential upside of 253.90%. Given Evommune's stronger consensus rating and higher possible upside, analysts plainly believe Evommune is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86

In the previous week, Evommune had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 11 mentions for Evommune and 8 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 0.60 beat Evommune's score of -0.15 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Evommune has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Evommune's return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Evommune	N/A	N/A	N/A

Summary

Evommune beats Adaptive Biotechnologies on 10 of the 16 factors compared between the two stocks.

How does Evommune compare to uniQure?

Evommune (NYSE:EVMN) and uniQure (NASDAQ:QURE) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

78.8% of uniQure shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Evommune has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	35.72	-$68.87M	-$9.50	N/A
uniQure	$16.10M	163.79	-$198.97M	-$3.48	N/A

Evommune presently has a consensus target price of $45.63, suggesting a potential upside of 253.90%. uniQure has a consensus target price of $64.17, suggesting a potential upside of 53.47%. Given Evommune's stronger consensus rating and higher probable upside, equities research analysts plainly believe Evommune is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.86
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

In the previous week, uniQure had 16 more articles in the media than Evommune. MarketBeat recorded 27 mentions for uniQure and 11 mentions for Evommune. uniQure's average media sentiment score of 0.73 beat Evommune's score of -0.15 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Evommune's return on equity of 0.00% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
uniQure	-1,154.42%	-145.81%	-27.15%

Summary

Evommune and uniQure tied by winning 8 of the 16 factors compared between the two stocks.

Get Evommune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVMN vs. The Competition

Export

Metric	Evommune	Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$461.76M	$3.11B	$4.46B	$23.33B
Dividend Yield	N/A	15.23%	17.12%	4.00%
P/E Ratio	-1.36	13.54	23.49	31.40
Price / Sales	35.72	2,864.06	167.68	21.93
Price / Cash	N/A	26.14	35.72	25.23
Price / Book	1.98	5.15	13.25	4.81
Net Income	-$68.87M	-$34.63M	$113.80M	$1.07B
7 Day Performance	-46.28%	1.07%	1.45%	1.74%
1 Month Performance	-34.96%	-1.24%	-2.29%	2.76%
1 Year Performance	N/A	12.63%	11.24%	19.96%

Evommune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVMN Evommune	2.3037 of 5 stars	$12.89 +0.6%	$45.63 +253.9%	N/A	$461.76M	$13M	N/A	45	News Coverage Analyst Downgrade
DYN Dyne Therapeutics	2.6179 of 5 stars	$20.61 +1.4%	$33.85 +64.2%	+151.0%	$3.36B	N/A	N/A	100	Insider Trade
IDYA IDEAYA Biosciences	3.5705 of 5 stars	$36.29 +0.0%	$50.69 +39.7%	+71.3%	$3.19B	$218.71M	N/A	80
ALMS Alumis	2.8781 of 5 stars	$25.03 +0.7%	$40.30 +61.0%	+782.1%	$3.17B	$24.05M	N/A	N/A	News Coverage
ADPT Adaptive Biotechnologies	2.4503 of 5 stars	$20.25 +4.7%	$20.33 +0.4%	+99.9%	$3.10B	$276.98M	N/A	790	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EVMN) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evommune (EVMN) Competitors

EVMN vs. DYN, IDYA, ALMS, ADPT, and QURE

How does Evommune compare to Dyne Therapeutics?

Summary

How does Evommune compare to IDEAYA Biosciences?

Summary

How does Evommune compare to Alumis?

Summary

How does Evommune compare to Adaptive Biotechnologies?

Summary

How does Evommune compare to uniQure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evommune (EVMN) Competitors

EVMN vs. DYN, IDYA, ALMS, ADPT, and QURE

How does Evommune compare to Dyne Therapeutics?

Does the media prefer DYN or EVMN?

Do institutionals & insiders hold more shares of DYN or EVMN?

Is DYN or EVMN more profitable?

Which has better earnings & valuation, DYN or EVMN?

Do analysts rate DYN or EVMN?

Summary

How does Evommune compare to IDEAYA Biosciences?

Do institutionals and insiders hold more shares of IDYA or EVMN?

Does the media prefer IDYA or EVMN?

Do analysts recommend IDYA or EVMN?

Is IDYA or EVMN more profitable?

Which has preferable earnings & valuation, IDYA or EVMN?

Summary

How does Evommune compare to Alumis?

Do analysts recommend EVMN or ALMS?

Which has higher earnings and valuation, EVMN or ALMS?

Does the media favor EVMN or ALMS?

Is EVMN or ALMS more profitable?

Summary

How does Evommune compare to Adaptive Biotechnologies?

Which has stronger valuation & earnings, ADPT or EVMN?

Do analysts rate ADPT or EVMN?

Does the media favor ADPT or EVMN?

Do institutionals & insiders believe in ADPT or EVMN?

Is ADPT or EVMN more profitable?

Summary

How does Evommune compare to uniQure?

Do institutionals and insiders have more ownership in EVMN or QURE?

Which has higher valuation & earnings, EVMN or QURE?

Do analysts prefer EVMN or QURE?

Does the media favor EVMN or QURE?

Is EVMN or QURE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVMN vs. The Competition

Evommune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools